Hi-Tech Pharmacal third-quarter revenues up 18% with "strong" sales from branded OTCs.
This article was originally published in The Tan Sheet
HI-TECH PHARMACAL THIRD-QUARTER SALES RISE 18% to $4.7 mil. for the period ended Jan. 31. The company attributed the increase to "strong sales" by its Health Care Products division and a contribution from Rose Labs, which was acquired in November 1994. The Health Care division sells company-brand OTCs under the H-T, Sooth-It and Diabetic Tussin brands. Rose Labs manufactures private-label suppository products ("The Tan Sheet" Nov. 7, 1994, In Brief)
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.